176 related articles for article (PubMed ID: 35417530)
1. Induction of Synthetic Lethality by Activation of Mitochondrial ClpP and Inhibition of HDAC1/2 in Glioblastoma.
Nguyen TTT; Shang E; Schiffgens S; Torrini C; Shu C; Akman HO; Prabhu VV; Allen JE; Westhoff MA; Karpel-Massler G; Siegelin MD
Clin Cancer Res; 2022 May; 28(9):1881-1895. PubMed ID: 35417530
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of HDAC1/2 Along with TRAP1 Causes Synthetic Lethality in Glioblastoma Model Systems.
Nguyen TTT; Zhang Y; Shang E; Shu C; Quinzii CM; Westhoff MA; Karpel-Massler G; Siegelin MD
Cells; 2020 Jul; 9(7):. PubMed ID: 32664214
[TBL] [Abstract][Full Text] [Related]
3. Combined HDAC and Bromodomain Protein Inhibition Reprograms Tumor Cell Metabolism and Elicits Synthetic Lethality in Glioblastoma.
Zhang Y; Ishida CT; Ishida W; Lo SL; Zhao J; Shu C; Bianchetti E; Kleiner G; Sanchez-Quintero MJ; Quinzii CM; Westhoff MA; Karpel-Massler G; Canoll P; Siegelin MD
Clin Cancer Res; 2018 Aug; 24(16):3941-3954. PubMed ID: 29764852
[No Abstract] [Full Text] [Related]
4. Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma.
Ishida CT; Zhang Y; Bianchetti E; Shu C; Nguyen TTT; Kleiner G; Sanchez-Quintero MJ; Quinzii CM; Westhoff MA; Karpel-Massler G; Prabhu VV; Allen JE; Siegelin MD
Clin Cancer Res; 2018 Nov; 24(21):5392-5406. PubMed ID: 30037819
[No Abstract] [Full Text] [Related]
5. HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models.
Nguyen TTT; Zhang Y; Shang E; Shu C; Torrini C; Zhao J; Bianchetti E; Mela A; Humala N; Mahajan A; Harmanci AO; Lei Z; Maienschein-Cline M; Quinzii CM; Westhoff MA; Karpel-Massler G; Bruce JN; Canoll P; Siegelin MD
J Clin Invest; 2020 Jul; 130(7):3699-3716. PubMed ID: 32315286
[TBL] [Abstract][Full Text] [Related]
6. Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosis.
Borsuk R; Zhou L; Chang WI; Zhang Y; Sharma A; Prabhu VV; Tapinos N; Lulla RR; El-Deiry WS
Am J Cancer Res; 2021; 11(9):4607-4623. PubMed ID: 34659909
[TBL] [Abstract][Full Text] [Related]
7. Enhanced efficacy of histone deacetylase inhibitor combined with bromodomain inhibitor in glioblastoma.
Meng W; Wang B; Mao W; Wang J; Zhao Y; Li Q; Zhang C; Tang Y; Ma J
J Exp Clin Cancer Res; 2018 Oct; 37(1):241. PubMed ID: 30285808
[TBL] [Abstract][Full Text] [Related]
8. OGDH and Bcl-xL loss causes synthetic lethality in glioblastoma.
Nguyen TT; Torrini C; Shang E; Shu C; Mun JY; Gao Q; Humala N; Akman HO; Zhang G; Westhoff MA; Karpel-Massler G; Bruce JN; Canoll P; Siegelin MD
JCI Insight; 2024 Mar; 9(8):. PubMed ID: 38483541
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality.
Ishizawa J; Zarabi SF; Davis RE; Halgas O; Nii T; Jitkova Y; Zhao R; St-Germain J; Heese LE; Egan G; Ruvolo VR; Barghout SH; Nishida Y; Hurren R; Ma W; Gronda M; Link T; Wong K; Mabanglo M; Kojima K; Borthakur G; MacLean N; Ma MCJ; Leber AB; Minden MD; Houry W; Kantarjian H; Stogniew M; Raught B; Pai EF; Schimmer AD; Andreeff M
Cancer Cell; 2019 May; 35(5):721-737.e9. PubMed ID: 31056398
[TBL] [Abstract][Full Text] [Related]
10. Krüppel-like factor 9 and histone deacetylase inhibitors synergistically induce cell death in glioblastoma stem-like cells.
Tung B; Ma D; Wang S; Oyinlade O; Laterra J; Ying M; Lv SQ; Wei S; Xia S
BMC Cancer; 2018 Oct; 18(1):1025. PubMed ID: 30348136
[TBL] [Abstract][Full Text] [Related]
11. Imipridone Anticancer Compounds Ectopically Activate the ClpP Protease and Represent a New Scaffold for Antibiotic Development.
Jacques S; van der Sloot AM; C Huard C; Coulombe-Huntington J; Tsao S; Tollis S; Bertomeu T; Culp EJ; Pallant D; Cook MA; Bonneil E; Thibault P; Wright GD; Tyers M
Genetics; 2020 Apr; 214(4):1103-1120. PubMed ID: 32094149
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma.
Zhang Y; Ishida CT; Shu C; Kleiner G; Sanchez-Quintero MJ; Bianchetti E; Quinzii CM; Westhoff MA; Karpel-Massler G; Siegelin MD
Sci Rep; 2018 May; 8(1):7373. PubMed ID: 29743557
[TBL] [Abstract][Full Text] [Related]
13. Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems.
Shang E; Zhang Y; Shu C; Ishida CT; Bianchetti E; Westhoff MA; Karpel-Massler G; Siegelin MD
Sci Rep; 2018 Oct; 8(1):15383. PubMed ID: 30337641
[TBL] [Abstract][Full Text] [Related]
14. Characterization of TR-107, a novel chemical activator of the human mitochondrial protease ClpP.
Fennell EMJ; Aponte-Collazo LJ; Wynn JD; Drizyte-Miller K; Leung E; Greer YE; Graves PR; Iwanowicz AA; Ashamalla H; Holmuhamedov E; Lang H; Karanewsky DS; Der CJ; Houry WA; Lipkowitz S; Iwanowicz EJ; Graves LM
Pharmacol Res Perspect; 2022 Aug; 10(4):e00993. PubMed ID: 35929764
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms.
Pinkerneil M; Hoffmann MJ; Deenen R; Köhrer K; Arent T; Schulz WA; Niegisch G
Mol Cancer Ther; 2016 Feb; 15(2):299-312. PubMed ID: 26772204
[TBL] [Abstract][Full Text] [Related]
16. Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells.
Grinshtein N; Rioseco CC; Marcellus R; Uehling D; Aman A; Lun X; Muto O; Podmore L; Lever J; Shen Y; Blough MD; Cairncross GJ; Robbins SM; Jones SJ; Marra MA; Al-Awar R; Senger DL; Kaplan DR
Oncotarget; 2016 Sep; 7(37):59360-59376. PubMed ID: 27449082
[TBL] [Abstract][Full Text] [Related]
17. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.
Stubbs MC; Kim W; Bariteau M; Davis T; Vempati S; Minehart J; Witkin M; Qi J; Krivtsov AV; Bradner JE; Kung AL; Armstrong SA
Clin Cancer Res; 2015 May; 21(10):2348-58. PubMed ID: 25688158
[TBL] [Abstract][Full Text] [Related]
18. Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma.
Nepali K; Hsu TI; Hsieh CM; Lo WL; Lai MJ; Hsu KC; Lin TE; Chuang JY; Liou JP
Eur J Med Chem; 2021 May; 217():113338. PubMed ID: 33744690
[TBL] [Abstract][Full Text] [Related]
19. Enhanced efficacy of histone deacetylase inhibitor panobinostat combined with dual PI3K/mTOR inhibitor BEZ235 against glioblastoma.
Meng W; Wang B; Mao W; Wang J; Zhao Y; Li Q; Zhang C; Ma J
Nagoya J Med Sci; 2019 Feb; 81(1):93-102. PubMed ID: 30962658
[TBL] [Abstract][Full Text] [Related]
20. Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma.
Singh MM; Johnson B; Venkatarayan A; Flores ER; Zhang J; Su X; Barton M; Lang F; Chandra J
Neuro Oncol; 2015 Nov; 17(11):1463-73. PubMed ID: 25795306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]